Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.